13
Jun
2024

Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Merck Bets on the Eye, Merus Raises a Fortune, & Roche Leadership Change
Biogen Buys HI-Bio, Endeavor Reverses Lung Scarring, & Pfizer’s Latest Cuts